Phase 2 Breast Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are female and have been newly diagnosed with ductal carcinoma in situ (DCIS) and/or invasive breast cancer, confirmed by a tissue sample analysis.
• People who were between 45 and 79 years old at the time of diagnosis.
• People who have already had a lumpectomy (surgery to remove the tumour while keeping the breast) where the edges of the removed tissue were found to be clear of cancer cells.
• People whose tumour is classified as an early stage (Tis, T1, or T2), and if T2, the tumour must be no larger than 3 cm across.
• People whose cancer tests positive for HER2 (a specific protein), where the treating doctor has prescribed HER2-targeted treatment as part of their care.
• People with invasive breast cancer who have had a procedure to check the lymph nodes under the arm, with results confirming no cancer was found in those nodes (with some exceptions — confirm with trial site).
• People aged 70 or older with a specific tumour profile (ER+, PR+, HER2-negative, low-to-intermediate grade, tumour 2 cm or smaller) may not be required to have the lymph node procedure, provided they agree to follow recommendations about a type of hormone-blocking medication called an aromatase inhibitor (confirm with trial site).
• People who are able to understand the study information and are willing to sign a written consent form in English.

Who may not be able to join:

• People who are currently pregnant or breastfeeding.
• People who have an active collagen-vascular disease (a group of conditions affecting connective tissue, such as lupus or scleroderma).
• People who have Paget's disease of the breast (a rare form of breast cancer affecting the nipple area).
• People who have a previous history of DCIS or invasive breast cancer before their current diagnosis.
• People who have previously received radiation therapy to the breast or chest area for any reason.
• People whose cancer is found in more than one separate area of the breast (multicentric carcinoma).
• People who have breast cancer in both breasts at the same time.
• People whose surgical margins (edges of the removed tissue) cannot be assessed under a microscope, or where cancer cells were found at the margins.
• People where the surgical cavity (the area left after the tumour was removed) cannot be clearly identified by the treating doctor.
• People whose treatment planning does not meet the specific radiation dose requirements set out in the study guidelines (confirm with trial site).
• People who, in the opinion of the treating doctor, have a medical, psychological, or social condition that could increase risk or make it difficult to follow the study requirements.

Important: Always verify eligibility with the trial site directly before applying.